Ziad Mallat

This paper shows that introducing the IL6RA Glu357Ala substitution in mice reduces atherosclerosis and AAA, similar to the human IL6RA Asp358Ala variant's protective effect.

This paper develops a third-generation IL-2 therapeutic that targets inflamed tissues via oxidation-specific epitopes, showing improved therapeutic benefit in multiple inflammation models.

This study identifies STING-IRF3-mediated epigenetic programming of macrophages as a driver of inflammation in aortic dissection, showing its role in pro-inflammatory bias and therapeutic potential.

This study identifies MAIT cells as contributors to atherosclerosis through monocyte-driven inflammation, showing their enrichment in plaques and protective effects when depleted.

This study shows that platelet inhibition increases rupture risk in early abdominal aortic aneurysm models in mice.

The paper investigates the effect of the IL6R-Asp358Ala variant on AAA growth and evaluates IL-6 pathway blockade in mouse models, finding no significant growth rate reduction but improved survival with trans-signalling inhibition.